Why most dental implants do not need bone grafting

A patient came in last month with a quote for two upper molar implants. The plan called for bilateral sinus lifts, a particulate xenograft on each side, a six-month healing period before fixture placement, and a total of $14,800 AUD before any crown work began. The clinic was reputable, the prosthodontist competent, the quote internally consistent. CBCT imaging showed 6.2 mm of residual ridge on the right and 5.8 mm on the left. After the appointment I placed two short implants in a single visit, no graft, healing caps that day. Total cost — including the existing CBCT reading and a single-tooth zirconia crown per side at the eight-week mark — came to roughly $7,400 AUD.

This is not a story about my superiority. The alternative protocol was published in 2016, validated in a meta-analysis the same year, and is taught in every Australian implant continuing-education course I have audited. It is the story of a financial gravitational pull that bends recommendation patterns toward grafting in cosmetic-heavy and high-volume international markets, regardless of whether the case in front of the clinician needs it.

This is the framework I use when a patient walks in with an implant treatment plan that includes bone grafting and asks whether they actually need it. It is not individual treatment advice. It is the structure of the decision so you can evaluate the recommendation you have received.

The four real indications for bone grafting

There are four — and only four — clinical situations where bone grafting is genuinely required before implant placement:

1. Severe atrophic ridge with less than 4 mm of vertical bone in a position where short implants, tilted implants, and zygomatic options are all contraindicated by anatomy. This is uncommon. In a well-screened sample of a general implant population, severe atrophy of this kind sits in the 8–12% range.
2. Pneumatised maxillary sinus with less than ~5 mm of subantral bone in a single tooth position where the prosthetic plan cannot be redesigned to use a tilted or zygomatic alternative. Sinus floor augmentation has good evidence behind it; the question is not whether it works but whether the prosthetic plan was designed to need it.
3. Buccal plate dehiscence discovered at the time of placement, where simultaneous guided bone regeneration is required to maintain the buccal contour. This is a same-visit procedure, not a separate staged graft, and should not appear on a treatment plan as a six-month delay.
4. Aesthetic-zone soft-tissue and hard-tissue deficit in a high smile line, where the alternative is a visible black triangle or a vertically asymmetric gingival margin. The prosthetic stakes are real here. The pricing — and the framing — should still be transparent.

If a treatment plan calls for a separate, staged, six-month bone grafting procedure on a non-aesthetic-zone tooth in someone with at least 5 mm of residual ridge, the burden is on the clinician to explain why none of the four alternatives below were considered. It is not on the patient to ask the question.

The four alternatives that often eliminate the need to graft

These are not exotic. They are mainstream protocols with peer-reviewed evidence and decade-plus follow-up data:

Short implants (6 mm and 8 mm fixtures). A 2016 systematic review of 19 randomised studies found short implants achieved survival rates statistically equivalent to longer implants placed with sinus augmentation, at lower cost and lower morbidity, in posterior atrophic jaws [1]. The technique requires a fixture that is engineered for a low crown-to-implant ratio — Straumann SLActive, Bicon, MegaGen, and several others have validated short-implant lines.

Tilted implants. Implants placed at angles up to 45° to the occlusal plane, anchored in remaining bone anterior to the maxillary sinus or distal to the mental foramen. The 2012 Del Fabbro systematic review pooled 13 studies and 1,958 implants, reporting 97.6% one-year survival and 96.8% three-year survival on tilted fixtures supporting fixed full-arch prostheses [2]. The original All-on-4 protocol [3] uses two anterior axial implants and two posterior tilted implants specifically to avoid the need for sinus grafting.

Zygomatic implants. For severe maxillary atrophy, fixtures anchored in the zygomatic bone bypass the sinus entirely. 2016 systematic review reports a pooled survival of 96.7% across 9,489 zygomatic implants in 2,402 patients, with mean follow-up over 36 months [4]. Specialist procedure, requires named training, but eliminates sinus grafting in the patient population where sinus grafting is most often quoted.

Prosthetic redesign. Sometimes the answer is “fewer implants in different positions.” A patient quoted for six implants and bilateral sinus lifts to support a fixed bridge can often be reframed as four implants — two anterior axial, two posterior tilted — with no grafting and a fixed prosthesis. This is not a technical compromise; it is a textbook protocol. The 2016 ITI Consensus Conference report on bone augmentation [5] explicitly identifies prosthetic redesign as the first-line consideration before grafting is recommended.

When a treatment plan includes grafting and none of these four alternatives appears in the same plan as a documented “considered and ruled out” line, the plan has not been worked up. It has been quoted.

Why grafting is over-recommended

I am not suggesting that every clinician who recommends grafting is acting on financial incentive. The pattern is more structural. Three reinforcing pressures:

Margin. A bilateral sinus lift adds $4,000–7,000 AUD or $1,800–3,400 USD to a treatment plan in international markets. Particulate xenograft material is fast-moving stock with strong distributor relationships. The economics of a high-volume implant practice change materially with whether grafting is the default or the exception.

Risk aversion (in the wrong direction). A grafted site placed at six months has more bone than the same site placed at zero months. Therefore the post-placement radiograph looks better. Therefore the protocol feels safer. The studies above show the survival difference is not real at five years; the radiographic difference is. Many clinicians optimise for what they can show the patient at the placement appointment.

Training cohort effects. A clinician trained in the early 2000s on a “graft first, place second” curriculum will continue to recommend that protocol unless they actively retrain on short and tilted implant techniques. The body of evidence supporting alternatives is published; whether the local clinical community has read it is variable.

In the dental tourism context, all three pressures are amplified. Margins are tighter, throughput is higher, and the training-cohort effect is more pronounced because the international market relies on protocols established when the clinic opened, not protocols updated against the current literature.

The cost numbers, with currency and what’s-included

For a single posterior maxillary tooth site, ~6 mm residual ridge, no aesthetic zone:

Numbers reflect quoted prices at four Australian specialist implant practices and four ISO-certified Vietnamese clinics, Q2 2026. Excludes CBCT (~$220 AUD / ~$60 USD), travel, accommodation, and consultation. Premium-tier fixtures (Straumann SLActive, Nobel Biocare TiUltra) included; economy-tier fixtures reduce Australian numbers by roughly 20%, Vietnamese by roughly 35%.

Two things matter in this table:

1. The short-implant pathway is the cheapest in both markets, often by a factor of two or more, with equivalent five-year survival per the 2016 meta-analysis. If a clinic has not quoted this pathway, the question is not “do they offer it?” — the question is “why was it not offered for your case?”
2. The international cost saving is real, but the savings on grafting are misleading. A Vietnamese clinic quoting $2,200 for sinus lift + implant + crown looks like a 70% saving on the Australian $7,400 equivalent. Both are reasonable prices for that pathway. Neither is a reasonable price compared to the $1,400–2,400 short-implant pathway you may not have been quoted in either country.

What the imaging should show

Every implant treatment plan should be supported by CBCT imaging. Not a panoramic radiograph. Not a periapical. A cone-beam CT scan that shows the residual ridge in three dimensions, the position of the maxillary sinus or mandibular nerve, and any anatomical constraints on placement.

If you are quoted for grafting and the only imaging on file is a 2D panoramic radiograph, the plan was not designed for your anatomy. It was designed for a category. Ask for the CBCT before committing. CBCT imaging is $220 AUD or about $60 USD; not having it is the false economy.

When a CBCT is reviewed, a clinician offering all four alternatives should be able to point at the scan and tell you specifically: “This is why a short implant is not viable here,” or “This is why we cannot tilt the distal fixture without compromising the prosthetic plan.” That conversation, anchored in the imaging, is what a worked-up plan looks like.

When grafting is genuinely the right answer

Specifically:

• Severe atrophy where short, tilted, and zygomatic alternatives are all contraindicated. Genuine, but rare in a well-screened sample.
• Aesthetic-zone soft-tissue and hard-tissue grafts in a high smile line, where the prosthetic stakes are visible. The conversation here is about aesthetic outcome, not about implant survival.
• Buccal plate dehiscence at the time of placement, addressed simultaneously, no staged delay.
• Vertical ridge augmentation in the anterior mandible where the prosthetic plan cannot be redesigned and the patient explicitly rejects an overdenture alternative.

In a standard implant practice, the proportion of cases where grafting is the right answer sits somewhere in the 15–25% range. The proportion where it is the recommended answer in international high-volume markets is closer to 60–75%. That gap is not clinical. It is structural.

What would change my view

I hold this position because of (a) my own caseload and the cases that come to me for second opinion, (b) the systematic reviews cited above, and (c) the 2016 ITI Consensus Conference report explicitly recommending prosthetic redesign and short/tilted alternatives as first-line considerations. The evidence that would update it:

• A registry-grade five-year cohort study, N>5,000, comparing matched cases (same residual bone, same prosthetic plan) randomised to graft-then-place vs short or tilted alternatives, with implant survival, peri-implantitis incidence, and patient-reported outcomes as endpoints, with stratification by clinic type. No such study exists. The closest comparators are non-randomised cohorts with significant selection bias.
• A demonstration that the published five-year survival equivalence between short and graft-supported standard implants does not extend to ten or fifteen years at scale. The mid-term data we have is reassuring; the long-term data is sparse.
• A demonstration that current particulate xenograft materials produce vital bone of equivalent quality to native bone at the implant interface, rather than radio-opaque fill that survives but does not biologically integrate to the same standard. The histological evidence on this is mixed.

Until those exist, the framework above is the framework I will continue to apply.

How to evaluate the treatment plan you have received

If you have been quoted for an implant treatment plan that includes bone grafting, ask:

1. What is the residual ridge dimension on CBCT? A specific number in millimetres, vertical and buccolingual, at the proposed implant position. Not “you don’t have enough bone.”
2. Was a short implant considered? If yes, on what specific anatomical or biomechanical grounds was it ruled out? If no, why not?
3. Was a tilted implant considered? Same question. The All-on-4 protocol and its single-tooth analogues are mainstream — a clinic that does not offer them has chosen not to, and that choice should be named.
4. Was a zygomatic alternative considered for severe maxillary atrophy? This is a specialist-only procedure, but the question is whether referral to a specialist who does it was offered.
5. What is the cost of the short-implant pathway at this clinic, with currency, date, and what’s-included specified? If the clinic does not quote a short-implant pathway at all, that is information.
6. Where would the graft material come from? Particulate xenograft (bovine), allograft (human cadaver), autogenous (your own bone, harvested separately), or synthetic alloplast? Each has different evidence, different costs, and different patient-side considerations. A clinic that is vague about the answer has not thought it through.

A clinician who answers all six clearly is a clinician you can trust on this question. A clinician who answers any of them by saying “we always graft first, that’s how we do it” has revealed the protocol — they have not justified the recommendation. The question of whether to graft is not a matter of clinic philosophy. It is a matter of your specific anatomy and prosthetic plan, and you are entitled to that answer in those terms.

For the broader implant cost comparison across countries, see the implant cost comparison reference. For the failed-root-canal decision framework on whether to pursue an implant at all, see when to save a tooth and when to replace it. For the trust-gap structural argument behind why these patterns persist in international markets, see the dental tourism trust gap.